


Facts & Figures



Global Footprint

17 state-of-the-art production facilities (incl. 4 Joint Ventures) | **15** countries, including all major pharma hubs



100% focus on our core expertise

Pharma drug containment and delivery solutions



€986

million revenue*
(+5.8% at constant currencies)

€280

million EBITDA
Margin: 28.4 %



>1,300

patents, patent applications, utility models, and designs filed by R&D team

125

employees in R&D, collaborating with a network of partners

On average, **more than 30,000 injections per minute** are provided to patients worldwide through a SCHOTT Pharma product.

>13

billion products delivered every year



Glass syringes



Polymer syringes



Cartridges



Vials



Ampoules



Broad ready-to-use portfolio

*All figures in this document refer to the financial year 2025.



Market & Customers

The **top 30** global pharma companies use SCHOTT Pharma's solutions.

>1,800

customers worldwide



Big pharma innovators



Leading CDMOs



Biotechs & start-ups

Growth opportunities from structural trends

GLP-1 drugs

Increasing demand to treat type-2 diabetes, obesity



SCHOTT Pharma has long-term contracts with the leading GLP-1 players

Antibody-drug conjugates (ADCs)

Innovative ADC therapies need to be lyophilized to ensure drug efficacy



SCHOTT Pharma offers specialty vials that fully eliminate fogging thanks to a hydrophobic inner coating

Homecare solutions

allow subcutaneous self-injection of small and large drug doses at home, thus reducing healthcare cost



SCHOTT Pharma contributes to fully integrated systems from device manufacturers with primary packaging, e.g. prefillable syringes and cartridges in small and large formats

Manufacturing transformation

Smaller patient populations require more flexible filling lines



SCHOTT Pharma offers pre-sterilized, ready-to-use products for utmost flexibility



ESG Responsibility



60%
reduced CO₂
emissions since 2019¹

100 %
Already using green
electricity worldwide



Closed-loop
recycling pilot
projects started
e.g. polymer trays for
vials

Vials with reduced product
carbon footprint
available from 2027²



~4.800

employees from over

>65


nationalities

>40%

female employees

~23 %

of leadership positions
held by women



Ownership



Executive Board



Dr. Christian Mias
CEO

Over 20 years leadership experience

CEO of SCHOTT Pharma since 2026

Previously Head of SCHOTT AG's
Electronic Packaging and Lighting &
Imaging business units

Ph.D. in Industrial Engineering



Reinhard Mayer
CFO

Over 30 years leadership experience

CFO of SCHOTT Pharma since 2025

Previous CFO roles with Nilfisk
Holding, Hansgrohe, and Getinge
Group

Master's Degree in Industrial
Engineering

¹ Scope 1 & 2; Defined as corporate CO₂ footprint of SCHOTT Pharma divided by number of good pieces sold (as of FY 2022)

² Approximately 30% CO₂ reduction for a 2 ml vial compared to current technology



SCHOTT Pharma's Governance

KGaA (Kommanditgesellschaft auf Aktien) is a listed partnership limited by shares with three corporate bodies:



General partner
(Komplementär)



Supervisory board
(Aufsichtsrat)



General shareholders' meeting
(Hauptversammlung)

As a **popular legal form** for companies originating from families or foundations, there are many **established KGaA** in Germany.

Supervisory Board

Shareholder representatives



Chairman

Peter Goldschmidt
CEO
Stada AG



Deputy Chairman

Dr. Wolfram Carius
Co-founder & advisor
Artistratis GmbH



Eva Kienle
Group CFO
Ramboll Group A/S



Ann-Kristin Erkens
CFO
SIG Group AG

Employee representatives



Mario Just
SCHOTT Pharma



Isabel Deister
SCHOTT Pharma

Press contact



Lea Kaiser



lea.kaiser@schott.com



+49 (0) 151/68 91 71 95



Katrin Schreyer



katrin.schreyer@schott.com



+49 (0) 171/11 67 54 4

